Results 281 to 290 of about 48,580 (292)

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes

Digestive Diseases and Sciences, 2018
Philip Jenkinson, Charlie Lees, Nikolas Plevris   +2 more
exaly  

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Inflammatory Bowel Diseases, 2018
Gionata Fiorino, Daniela Gilardi, Silvio Danese   +2 more
exaly  

Molecular Cytogenetics of t(12;21)(p13;q22)

Leukemia and Lymphoma, 1996
Olivier A Bernard, S P Romana, H Poirel
exaly  

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Digestive Diseases and Sciences, 2017
Angel Vilches-Arenas, Federico Argüelles-Arias   +1 more
exaly  

Derivative (1)t(1;19)(p13;p13) in the setting of myelofibrosis with JAK2 V617F

Cancer Genetics and Cytogenetics, 2009
John F. Staropoli, Martha Wadleigh, Paola Dal Cin   +2 more
openaire   +1 more source

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

Gastroenterology
Jean-Frédéric Colombel, Gahee Park, Maciej Kowalski   +2 more
exaly  

Translocation t(8;16)(p11;p13) in neonatal acute monocytic leukaemia

European Journal of Pediatrics, 1991
I Ono, N Moriyama
exaly  

P13 KINASE ANTAGONISTS

2009
KNIGHT ZACHARY A, SHOKAT KEVAN M, WILLIAMS OLESEGUN   +2 more
openaire   +4 more sources

Characterization of rtSH3p13 gene encoding a development protein involved in vesicular traffic in spermiogenesis

Cell Research, 2004
exaly  

P13 Drug Resistance

Helicobacter, 2008
openaire   +1 more source